Comparing Osiris Therapeutics (OTCMKTS:OSIR) & AIM ImmunoTech (NYSEAMERICAN:AIM)

Osiris Therapeutics (OTCMKTS:OSIR) and AIM ImmunoTech (NYSEAMERICAN:AIM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Valuation & Earnings

This table compares Osiris Therapeutics and AIM ImmunoTech”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A
AIM ImmunoTech	$170,000.00	40.17	-$17.32 million	($24.68)	-0.10

Osiris Therapeutics has higher earnings, but lower revenue than AIM ImmunoTech.

Analyst Recommendations

This is a breakdown of current recommendations for Osiris Therapeutics and AIM ImmunoTech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Osiris Therapeutics	0	0	0	0	0.00
AIM ImmunoTech	0	0	1	1	3.50

AIM ImmunoTech has a consensus price target of $275.00, suggesting a potential upside of 10,812.70%. Given AIM ImmunoTech’s stronger consensus rating and higher probable upside, analysts plainly believe AIM ImmunoTech is more favorable than Osiris Therapeutics.

Profitability

This table compares Osiris Therapeutics and AIM ImmunoTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Osiris Therapeutics	N/A	N/A	N/A
AIM ImmunoTech	-13,360.33%	-1,586.23%	-198.52%

Insider and Institutional Ownership

0.3% of Osiris Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 43.4% of Osiris Therapeutics shares are owned by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

AIM ImmunoTech beats Osiris Therapeutics on 6 of the 10 factors compared between the two stocks.

About Osiris Therapeutics

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.